Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 2000, p. 2130-2132, Vol. 44, No. 8
Centers for Disease Control and Prevention,
Atlanta, Georgia 30333
Received 29 December 1999/Returned for modification 26 April
2000/Accepted 24 May 2000
Facklamia spp. are gram-positive cocci, arranged in
short chains or diplos, and resemble viridans streptococci on 5% sheep blood agar. Eighteen strains representing four species of
Facklamia were isolated from blood cultures, an abscess,
bone, cerebrospinal fluid, gall bladder, vaginal swab, and one unknown
source. Cultures were tested against 15 antimicrobial agents by using
the broth microdilution MIC method. Reduced susceptibilities to the
beta lactams, erythromycin, clindamycin, trimethoprim-sulfamethoxazole, and tetracycline were found. These results indicate that the
susceptibilities of the Facklamia species are varied and
that some strains have resistance patterns which may present difficulty
in managing systemic infections in patients.
Since the first description of a
Facklamia species in 1997, four additional species of this
genus have been described (2-5, 11). These
species, Facklamia hominis, Facklamia
ignava, Facklamia sourekii, and Facklamia
tabaciasalis, are most often arranged in chains, whereas
Facklamia languida is most often arranged in clusters with
very little chaining. The identification of these bacteria is
problematic since none of the rapid testing systems currently include them in their databases. In a previous study examining 120 strains of unidentified gram-positive cocci with phenotypic characteristics that eliminated them from the known genera
of bacteria, such as Aerococcus, Streptococcus,
Enterococcus, and Lactococcus, we identified 18 strains (21.6%) of bacteria as Facklamia species. These
carbon dioxide-enhanced bacteria were included in a group of previously
unidentified gram-positive cocci since they had an unusual
combination of positive reactions that included only leucine
aminopeptidase, L-pyrrolidonyl-B-naphthylamide, and
growth in 6.5% sodium chloride for genus identification
(8). The purpose of this study was to further the knowledge
of the clinical syndromes caused by Facklamia species and to
report on the antimicrobial susceptibility of these strains.
The strains tested were taken from the culture collection of the
Streptococcus laboratory at the Centers for Disease Control and Prevention. The majority of cultures were submitted to the Streptococcus laboratory for identification from various
state health departments throughout the United States (Table
1). Strains were identified according to
procedures previously described (10). Based on 10 tests used
to identify catalase-negative, gram-positive coccal genera, four genera
have similar phenotypic profiles for genus identification by
conventional tests: Alloiococcus otiditis, Ignavigranum ruoffiae, Dolosigranulum pigrum, and
Facklamia species (8, 10). Members of genus
Alloiococcus differ from the Ignavigranum, Dolosigranulum, and Facklamia species by their
aerobic nature (12). The majority of
Dolosigranulum cultures are positive for esculin hydrolysis,
while Ignavigranum and Facklamia species do not
hydrolyze esculin. Specific identification has been published previously (10).
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Antimicrobial Susceptibilities and Clinical Sources
of Facklamia Species
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
TABLE 1.
Source, clinical diagnosis, and demographic information
on 19 strains of Facklamia species
MICs were determined by using the methods described by the National Committee for Clinical Laboratory Standards (NCCLS) (13). The following 15 antimicrobial agents and concentration ranges were tested in customized panels (PML Microbiologicals, Wilsonville, Oreg.) by using the microdilution method in Mueller-Hinton broth supplemented with 3% lysed horse blood: penicillin, 0.03 to 16.0 µg/ml; amoxicillin, 0.03 to 8.0 µg/ml; cefotaxime, 0.06 to 16.0 µg/ml; cefuroxime, 0.12 to 32 µg/ml; erythromycin, 0.06 to 16 µg/ml; trimethoprim-sulfamethoxazole, 0.12/2.38 to 8/152 µg/ml; clindamycin, 0.06 to 2.0 µg/ml; chloramphenicol, 2.0 to 16.0 µg/ml; levofloxacin, 0.5 to 16 µg/ml; trovafloxcin, 0.25 to 8.0 µg/ml; meropenem, 0.06 to 2.0 µg/ml; vancomycin, 0.12 to 2.0 µg/ml; tetracycline, 1.0 to 8.0 µg/ml; and quinupristin-dalfopristin and rifampin only at dilutions 1.0 µg/ml and 4.0 µg/ml, respectively. The panels were incubated under 5% carbon dioxide for 22 to 24 h. The Facklamia species are facultatively anaerobic and grow best in an atmosphere of increased carbon dioxide. In most cases, the growth from a single 15- by 100-mm Trypticase soy-5% sheep blood agar plate was required to prepare a 0.5 McFarland density of the bacteria. Panels were read visually with the aid of a mirror panel viewer.
| |
RESULTS AND DISCUSSION |
|---|
|
|
|---|
Since it is likely that Facklamia species were previously identified as viridans streptococci, and were therefore probably included in previous studies of infections and antimicrobial susceptibility of viridans streptococci, it is of interest to note whether the clinical sources and antimicrobial susceptibility patterns of the Facklamia species differ from those of the viridans streptococci. Our studies seem to indicate that the types of infections caused by Facklamia species are similar to those caused by viridans streptococci and that the antimicrobial susceptibilities may also be similar; however, some differences are noted.
Of the 18 human isolates of the Facklamia species, 12 of the strains were isolated from blood cultures. The sources and age of the patients indicate that the Facklamia species are opportunistic pathogens, similar to the viridans streptococci. Only one nonsterile-source isolate from a vaginal swab was examined. The other five isolates were from an abscess, bone, cerebrospinal fluid, gall bladder, and an unknown source. In the original description of F. hominis, the authors described the identification of six isolates of this bacterium (2). Four of the six isolates were identified from female patients; the gender of the patients from whom the other two strains were isolated was not given (1). Of the 18 Facklamia cultures, the gender of 14 of the patients from whom these cultures were taken was provided: 13 of the 14 cultures were from female patients (Table 1). The fact that three of the six original strains were isolated from vaginal swabs may indicate that the female genitourinary tract is the natural habitat of the Facklamia species. This speculation demonstrates a difference between Facklamia and viridans streptococci: the natural habitat of the majority of viridans streptococci is the oropharynx (9).
The interpretation of resistant, intermediate, and susceptible was determined by using the NCCLS guidelines for Streptococcus species other than Streptococcus pneumoniae (13) for penicillin, amoxicillin, cefotaxime, erythromycin, clindamycin, chloramphenicol, levofloxacin, trovofloxacin, and tetracyline. The interpretive standards for S. pneumoniae were used for presumptive susceptibility values for cefuroxime, trimethoprim-sulfamethoxazole, vancomycin, and rifampin. No interpretive standards are available for meropenem and quinupristin-dalfopristin.
The cumulative MIC data for all the Facklamia species are
listed in Table 2. Seventeen percent of
the strains are intermediate to penicillin, 44% are resistant to
cefotaxime, and 33% are presumptively resistant to cefuroxime. There
are no breakpoints for meropenem at this time. Twenty-two percent of
the strains are resistant to erythromycin, and 33% are resistant to
clindamycin. Twenty-eight percent of the strains are presumptively
resistant to trimethoprim-sulfamethoxazole, and 17% of the strains are
presumptively resistant to rifampin. These numbers are not appreciably
different from those of more recent studies of viridans
streptococci (1, 6, 7).
|
There are differences in susceptibilities among the Facklamia species to various antimicrobials. Two of five F. ignava and one of four F. hominis isolates were intermediate to penicillin while all of the F. sourekii and F. languida isolates were susceptible. While none of the strains were resistant to amoxicillin, several strains were resistant to cefotaxime and were presumptively resistant to cefuroxime. One F. ignava, one F. sourekii, and all six F. languida isolates were resistant to cefotaxime while one F. hominis and five of the six F. languida isolates were presumptively resistant to cefuroxime. More strains of F. ignava (three of five) than F. languida (two of six) were resistant to erythromycin. Strains of the other two species were susceptible to erythromycin. However, this was not true for the susceptibilities of F. ignava (one of five) and F. languida (five of six strains), which were resistant to clindamycin. Presumptive resistance, either full or intermediate, to trimethoprim-sulfamethoxazole was present in most strains. None of the isolates were resistant to chloramphenicol, levofloxacin, trovafloxacin, or vancomycin. Three of the four strains of F. hominis were presumptively resistant to rifampin while all strains of the other three species were susceptible. Resistance to tetracycline was present in three of the four species (Table 2).
Although the number of strains of the Facklamia species tested are limited, there appear to be appreciable differences in antimicrobial susceptibility between species. This finding does not differ much from that among the viridans streptococci. However, Streptococcus mitis is more likely to be resistant to penicillin (6, 14), and Streptococcus oralis and S. mitis are more resistant to the macrolides (15). It is noteworthy that the majority of isolates are from female patients. This observation merits additional attention. There is a need for the manufacturers of commercial rapid identification kits for gram-positive cocci to include Facklamia species in their databases in order for additional studies to proceed.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Centers for Disease Control and Prevention, Mailstop C-02, Atlanta, GA 30333. Phone: (404) 639-1379. Fax: (404) 639-3123. E-mail: rrf{at}ecdc.gov.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Alcaide, F.,
J. Linares,
R. Pallares,
J. Carratala,
M. A. Benitez,
F. Gudiol, and R. Martin.
1995.
In vitro activities of 22 -lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood.
Antimicrob. Agents Chemother.
39:2243-2247[Abstract].
|
| 2. | Collins, M. D., E. Falsen, J. Lemozy, E. Akervall, B. Sjoden, and P. A. Lawson. 1997. Phenotypic and phylogenetic characterization of some Globicatella-like organisms from human sources: description of Facklamia hominis gen. nov., sp. nov. Int. J. Syst. Bacteriol. 43:880-882. |
| 3. |
Collins, M. D.,
R. A. Hutson,
E. Falsen, and B. Sjoden.
1999.
Facklamia sourekii sp. nov., isolated from human sources.
Int. J. Syst. Bacteriol.
49:635-638 |
| 4. |
Collins, M. D.,
R. A. Hutson,
E. Falsen, and B. Sjoden.
1999.
Facklamia tabacinasalis sp. nov., from powdered tobacco.
Int. J. Syst. Bacteriol.
49:1247-1250 |
| 5. |
Collins, M. D.,
P. A. Lawson,
R. Monasterio,
E. Falsen,
B. Sjoden, and R. R. Facklam.
1998.
Facklamia ignava sp. nov., isolated from clinical specimens.
J. Clin. Microbiol.
36:2146-2148 |
| 6. |
De Azavedo, J. C. S.,
L. Trpeski,
S. Pong-Porter,
S. Matsumura,
The Canadian Bacterial Surveillance Network, and D. E. Low.
1999.
In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci across Canada.
Antimicrob. Agents Chemother.
43:2299-2301 |
| 7. | Doern, G. V. M., J. Ferraro, A. B. Brueggemann, and K. L. Ruoff. 1996. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob. Agents Chemother. 40:891-894[Abstract]. |
| 8. | Facklam, R., and J. A. Elliott. 1995. Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci. Clin. Microbiol. Rev. 8:479-495[Abstract]. |
| 9. | Frandsen, E. V. G., V. Pedrazzoli, and M. Kilian. 1991. Ecology of viridans streptococci in the oral cavity and pharynx. Oral Microbiol. Immunol. 6:129-133[Medline]. |
| 10. |
LaClaire, L., and R. Facklam.
2000.
Comparison of three commercial rapid identification systems for the unusual gram-positive cocci Dolosigranulum pigrum, Ignavigranum ruoffiae, and Facklamia species.
J. Clin. Microbiol.
38:2037-2042 |
| 11. |
Lawson, P. A.,
M. D. Collins,
E. Falsen,
B. Sjoden, and R. R. Facklam.
1999.
Facklamia languida sp. nov., isolated from clinical human specimens.
J. Clin. Microbiol.
37:1161-1164 |
| 12. | Miller, P. H., R. R. Facklam, and J. M. Miller. 1996. Atmospheric growth requirements for Alloiococcus species and related gram-positive cocci. J. Clin. Microbiol. 34:1027-1028[Abstract]. |
| 13. | National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing, vol. 19. M100-S9. National Committee for Clinical Laboratory Standards, Wayne, Pa. |
| 14. | Pottumarthy, S., and A. J. Morris. 1998. Detection of decreased penicillin susceptibility in viridans group of streptococci. Pathology 30:188-191[CrossRef][Medline]. |
| 15. |
Teng, L. J.,
P. R. Hsueh,
Y. C. Chen,
S. W. Ho, and K. T. Luh.
1998.
Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis.
J. Antimicrob. Chemother.
41:621-627 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»